Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study (Q43571946)

24 November 2017

title

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study (English)

1 reference

24 November 2017

main subject

acute coronary syndrome

1 reference

1 reference

24 November 2017

1 reference

24 November 2017

A M Lincoff

1 reference

24 November 2017

R M Califf

1 reference

24 November 2017

E M Ohman

1 reference

24 November 2017

M S Lauer

1 reference

24 November 2017

M T Roe

1 reference

24 November 2017

H D Aronow

1 reference

24 November 2017

P L Houghtaling

1 reference

24 November 2017

K E Wolski

1 reference

24 November 2017

R A Harrington

1 reference

24 November 2017

N S Kleiman

1 reference

24 November 2017

M Keltai

1 reference

24 November 2017

R G Wilcox

1 reference

24 November 2017

A Vahanian

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

24 November 2017

1 reference

inferred from page(s)

published in

The Lancet

1 reference

24 November 2017

volume

357

1 reference

24 November 2017

issue

9262

1 reference

24 November 2017

page(s)

1063-1068

1 reference

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Comm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Statins and C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Effect of statins on C-reactive protein in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Cause of death in clinical research: time for a reassessment?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Estimating Causal Effects from Large Data Sets Using Propensity Scores

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Invited commentary: propensity scores

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Early statin treatment following acute myocardial infarction and 1-year survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Early beta-blocker therapy for acute myocardial infarction in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Use of cholesterol-lowering medications in the United States from 1991 to 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904257-4

7 January 2021

10.1016/S0140-6736(00)04257-4

Identifiers

DOI

1 reference

24 November 2017

1 reference